[4-iodo-5-(2-methoxy-ethoxy)-2-nitro-phenyl]-carbamic acid tert-butyl ester | 335349-67-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-iodo-5-(2-methoxy-ethoxy)-2-nitro-phenyl]-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[4-iodo-5-(2-methoxyethoxy)-2-nitrophenyl]carbamate
• CAS: 335349-67-2
• 化学式: C₁₄H₁₉IN₂O₆
• 分子量: 438.219
• InChiKey: RODXWLBCSMJAHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [4-iodo-5-(2-methoxy-ethoxy)-2-nitro-phenyl]-carbamic acid tert-butyl ester 、 4-氟苯硼酸 生成 [4'-fluoro-2-(2-methoxy-ethoxy)-5-nitro-biphenyl-4-yl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Glutamate receptor antagonists

  摘要：

  这项发明涉及具有公式1的基本结构的化合物。 公式I的化合物被证明具有作为代谢型谷氨酸受体拮抗剂的活性。

  公开号：

  US06407094B1
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以99%的产率得到[4-iodo-5-(2-methoxy-ethoxy)-2-nitro-phenyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: New potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1

  摘要：

  A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Attachment of an 8-(2-aryl)-ethynyl-moiety produced compounds inhibiting the binding of [H-3]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both mGIuR2 and mGluR3. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.026

文献信息

• BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1224174A2

  公开（公告）日：2002-07-24
• US6407094B1
  申请人：——

  公开号：US6407094B1

  公开（公告）日：2002-06-18
• [EN] BENZODIAZEPINE DERIVATIVES<br/>[FR] DERIVES DE BENZODIAZEPINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2001029011A2

  公开（公告）日：2001-04-26

  The present invention relates to compounds of general formula (I) wherein X is a single bond or an ethynediyl group, wherein, in case X is a single bond, R1 is halogen or phenyl which is optionally substituted with halogen, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, or cyano; In case X is an ethynediyl group, R1 is phenyl, optionally substituted with halogen, lower alkyl, halo-lower alkyl, lower cycloalkyl, lower alkoxy or halo-lower alkoxy; R3 is a 5 or 6 membered aryl or heteroaryl which are optionally substituted. The compounds according to the present invention can be used for treating or preventing acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.